Frequency Therapeutics — Hearing Loss Regeneration

So John Adams, Minbo Shim is kosher and Frequency Therapeutics are dodgy and sinister? That ain't right man, come on guy.
Minbo Shim isn't a threat to large American corporations. Plus he is already doing what he's doing and there is scientific evidence showing what he does is effective in humans and animals. And besides the main gatekeeper for the development schedule of FX-322 is the FDA, which is ran by an investment banker.
 
Fair play... is there a middle ground? I hear you. I'm frustrated as are you. Apologies.
Yeah there's even better place than middle ground, I might be wrong and FX-322 will get fast tracked and released soon and cure tinnitus, and Minbo Shim's treatment also cures tinnitus and 2019 may be the beginning of the end for this nonsense.
 
Hope so brother. I am trying to hold on for my family as you and many other are.
We all want some relief, especially if it's severe tinnitus. Mine is bad.
Wish things would speed up.
And like you hoping for FX-322 and Minbo Shim to work and be done with this "nonsense" and suffering. It really is tough to endure and it's taking its toll.
 
Will FX-322 help if I have severe hearing loss (80 dB)? Does it use supporting cells or scar tissue?
We can only know this when they release their clinical data. They've said they use multiplied supporting cells but the Stanford University dude seemed to indicate that scar cells can be turned into supporting cells. Good question.
If this drug works and it regrows new hairs, would that make the pain and fullness go away?
I'm hoping it heals everything. But only time will tell.
 
it's knee jerk conspiratorial thinking to assume biotech firms that are going to disrupt huge markets aren"t being approached by their competitors to make deals to soften the blow.
Hey, if you want to look at hearing loss regeneration as the equivalent of the mythical car that runs on water, be my guest. To me there is a difference between corporate misconduct (such as dieselgate) that is brought out into the public and blindly predicting that any and all revolutionary progress will be buried in order to protect the status quo.
 
Hey, if you want to look at hearing loss regeneration as the equivalent of the mythical car that runs on water, be my guest. To me there is a difference between corporate misconduct (such as dieselgate) that is brought out into the public and blindly predicting that any and all revolutionary progress will be buried in order to protect the status quo.
hahaha.
first off, you can use water and electricity to create hydrogen gas via electrolysis and that will definitely run an internal combustion engine. this is not mythical, it is established science.
maybe you need to stay in the shade jabrone.
 
Will McLean of Frequency Therapeutics is scheduled to present at the annual meeting of the Association for Research in Otolaryngology (ARO). The conference will be held 9-13 February 2019 in Baltimore, Maryland, USA.

The title of his presentation is:

Lgr5+ Cochlear Progenitor Cell Proliferation is Driven by the Combined Activation of the Wnt, Non-Canonical Notch, and PI3K Pathways

Abstracts of presentations will be made available closer to the conference. Here is the full list of presentations (search on tinnitus for a total of 71 mentions):

https://cdn.ymaws.com/www.aro.org/resource/resmgr/mwm2019/aro_session_information_2019.pdf

For more information on ARO:

https://www.aro.org/
 
Will McLean of Frequency Therapeutics is scheduled to present at the annual meeting of the Association for Research in Otolaryngology (ARO). The conference will be held 9-13 February 2019 in Baltimore, Maryland, USA.

The title of his presentation is:

Lgr5+ Cochlear Progenitor Cell Proliferation is Driven by the Combined Activation of the Wnt, Non-Canonical Notch, and PI3K Pathways

Abstracts of presentations will be made available closer to the conference. Here is the full list of presentations (search on tinnitus for a total of 71 mentions):

https://cdn.ymaws.com/www.aro.org/resource/resmgr/mwm2019/aro_session_information_2019.pdf

For more information on ARO:

https://www.aro.org/
Fantastic! Doubt he would go up on stage and present if the trial was a failure.
 
Fantastic! Doubt he would go up on stage and present if the trial was a failure.

He seems to be presenting on scientific research into cell proliferation and its driving factors, not necessarily on the drug FX-322. On the other hand, just the title of his presentation seems like he's pretty sure he knows what he's talking about. Let's wait and see.
 
Will FX-322 help if I have severe hearing loss (80 dB)? Does it use supporting cells or scar tissue?

I found this on the net: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637947/

Morphological analyses of human temporal bones in patients with severe or profound hearing loss have shown cochlear regions where differentiated support cells remain intact despite total hair cell loss, as well as regions where the organ has been replaced with a flat unspecialized epithelium (Teufert et al., 2006; Hoa et al., 2010). Severe-to-profoundly deaf patients with a viable auditory nerve are potential candidates for restorative therapies once therapies such as hair cell regeneration or stem cell implantation become a reality. Hence, research aimed towards identifying methods to biologically restore the damaged epithelium must focus both on the columnar support cells retained in the repaired columnar epithelium that continue to exhibit some specialized molecular and structural features​

So yeah it looks like it could help with severe and/or profound hearing loss. This is good news for all of us.
 
I found this on the net: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637947/

Morphological analyses of human temporal bones in patients with severe or profound hearing loss have shown cochlear regions where differentiated support cells remain intact despite total hair cell loss, as well as regions where the organ has been replaced with a flat unspecialized epithelium (Teufert et al., 2006; Hoa et al., 2010). Severe-to-profoundly deaf patients with a viable auditory nerve are potential candidates for restorative therapies once therapies such as hair cell regeneration or stem cell implantation become a reality. Hence, research aimed towards identifying methods to biologically restore the damaged epithelium must focus both on the columnar support cells retained in the repaired columnar epithelium that continue to exhibit some specialized molecular and structural features​

So yeah it looks like it could help with severe and/or profound hearing loss. This is good news for all of us.
I stand corrected to my former position of Frequency Therapeutics not helping, thank you for providing research.
 
I read from the Audion trial that they include people with mild/moderate hearing loss because then they are also able to measure negative effects if any occurs. I assume Frequency Therapeutics does it for the same reason. So the inclusion criteria is no indication of effectiveness for profound hearing loss.
 
The whole slight/mild/moderate/severe/profound is an incurrate outdated way of measuring hearing loss.

We already know hearing loss has a lot more to do with how well one hears in background noise, not pure tonal audiometry and the human voice range.

These hearing test were never designed to determine rather the cochlear spiral is damaged or not, just to make sure someone could hear enough to function in a quiet workplace environment.
 
They just finished their last trial and I'm sure they have asked themselves most if not all of these questions and have probably found an answer to most of them.
 
If this drug works and it regrows new hairs, would that make the pain and fullness go away?
Depends on what fullness means... large debate. I have it too. Could be a temporary hearing loss (weird), could be your skull/neck muscles, could be your sinus... could be a lot of things. I'm still trying to fix that (gives me dizziness feeling too) without trying to fix tinnitus.
 
Will McLean of Frequency Therapeutics is scheduled to present at the annual meeting of the Association for Research in Otolaryngology (ARO). The conference will be held 9-13 February 2019 in Baltimore, Maryland, USA.

The title of his presentation is:

Lgr5+ Cochlear Progenitor Cell Proliferation is Driven by the Combined Activation of the Wnt, Non-Canonical Notch, and PI3K Pathways

Abstracts of presentations will be made available closer to the conference. Here is the full list of presentations (search on tinnitus for a total of 71 mentions):

https://cdn.ymaws.com/www.aro.org/resource/resmgr/mwm2019/aro_session_information_2019.pdf

For more information on ARO:

https://www.aro.org/
I wonder if it is open to the public? I live in the area.
 
Two questions we need answers to:
1. How many, if any, of the trial participants reported having tinnitus.
2. From the groups that received FX-322, did any report a lowering of their tinnitus.

We are dying here. We need this information please! Please!
 
will all these researchers be able to give their lecture on their subject or is there a selection beforehand?
ARO has a selection process by which researchers submit their proposals for presentations for review and approval.

https://www.aro.org/page/AbstractGuidelines

I am not familiar with how this works beyond reading what is at this link. However, given that there are hundreds of presentations at ARO, my guess is that most probably are approved.
 
WOBURN, Mass., January 3, 2019 –

Frequency Therapeutics, a clinical stage biotechnology company, a clinical-stage biotechnology company, today announced that the Company will present at the upcoming 37th Annual JP Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019.

David Lucchino, Co-Founder and Chief Executive Officer of Frequency, will provide an overview of the company, its innovative platform, and its clinical stage asset for Hearing Regeneration.

Presentation details are as follows:

Date: Monday, January 7, 2019
Time: 12:00 p.m. PT
Location: Westin St. Francis, Elizabethan C/D


http://www.frequencytx.com/news-events/news-events-press-release-01-03-2019.php
 
WOBURN, Mass., January 3, 2019 –

Frequency Therapeutics, a clinical stage biotechnology company, a clinical-stage biotechnology company, today announced that the Company will present at the upcoming 37th Annual JP Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019.

David Lucchino, Co-Founder and Chief Executive Officer of Frequency, will provide an overview of the company, its innovative platform, and its clinical stage asset for Hearing Regeneration.

Presentation details are as follows:

Date: Monday, January 7, 2019
Time: 12:00 p.m. PT
Location: Westin St. Francis, Elizabethan C/D

http://www.frequencytx.com/news-events/news-events-press-release-01-03-2019.php
Can we assume, from this news, that phase 1a / 1b was successful?
 

Log in or register to get the full forum benefits!

Register

Register on Tinnitus Talk for free!

Register Now